



Supplementary Figure 4. Kaplan-Meier survival curves of mice evaluated in the preclinical trial. Overall survival across all 7 treatment arms for the **(a)** HR-deficient xenografts and **(b)** HR-proficient xenografts is shown. To account for regimen-related toxicity, the survival analyses were repeated using only mice that completed 28 days of treatment. **(c)** In HR-deficient xenografts, the gemcitabine-cisplatin arm again had longer survival than gemcitabine alone and gemcitabine-talazoparib. **(d)** There was no survival difference in HR-proficient xenografts. P-values represent log-rank comparisons of Kaplan-Meier survival curves. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$. Cis, cisplatin; Tal, talazoparib.